At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ABCL AbCellera Biologics
Market Closed 05-15 16:00:00 EDT
4.09
-0.31
-7.05%
盘后4.10
+0.01+0.29%
19:59 EDT
High4.28Low4.00Vol8.87M
Open4.26D1 Closing4.40Amplitude6.45%
Mkt Cap1.25BTradable Cap829.25MTotal Shares305.26M
T/O36.28MT/O Rate4.37%Tradable Shares202.75M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

AbCellera Biologics (ABCL) Q4 Revenue Surge Tests High 20.1x P/S Growth Narrative
Simply Wall St.  ·  05-13
AbCellera Biologics (ABCL) Q4 Revenue Surge Tests High 20.1x P/S Growth Narrative
AbCellera Biologics Bets Big on 2026 Trial Catalysts
TIPRANKS  ·  05-13
AbCellera Biologics Bets Big on 2026 Trial Catalysts
Stock Track | AbCellera Biologics Plummets 11.65% Intraday Amid Concerns Over Continued Losses and Rising R&D Expenses Despite Q1 Beat
Stock Track  ·  05-12
Stock Track | AbCellera Biologics Plummets 11.65% Intraday Amid Concerns Over Continued Losses and Rising R&D Expenses Despite Q1 Beat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: West Pharmaceutical Services (WST), CVRx (CVRX) and AbCellera Biologics (ABCL)
TIPRANKS  ·  05-12
Analysts’ Opinions Are Mixed on These Healthcare Stocks: West Pharmaceutical Services (WST), CVRx (CVRX) and AbCellera Biologics (ABCL)
Stock Track | AbCellera Biologics Plunges 5.47% in Pre-Market Amid Concerns Over Continued Losses and Rising R&D Expenses Despite Q1 Beat
Stock Track  ·  05-12
Stock Track | AbCellera Biologics Plunges 5.47% in Pre-Market Amid Concerns Over Continued Losses and Rising R&D Expenses Despite Q1 Beat
Analysts Offer Insights on Healthcare Companies: Ceribell, Inc. (CBLL) and AbCellera Biologics (ABCL)
TIPRANKS  ·  05-12
Analysts Offer Insights on Healthcare Companies: Ceribell, Inc. (CBLL) and AbCellera Biologics (ABCL)
Stock Track | AbCellera Biologics Plunges 7.24% Post-Market Despite Q1 Beat as Investors Focus on Continued Losses and Rising R&D Expenses
Stock Track  ·  05-12
Stock Track | AbCellera Biologics Plunges 7.24% Post-Market Despite Q1 Beat as Investors Focus on Continued Losses and Rising R&D Expenses
AbCellera Biologics options imply 9.7% move in share price post-earnings
TIPRANKS  ·  05-12
AbCellera Biologics options imply 9.7% move in share price post-earnings
Stock Track | AbCellera Biologics Plunges 6.48% After-Hours Despite Beating Q1 Estimates
Stock Track  ·  05-12
Stock Track | AbCellera Biologics Plunges 6.48% After-Hours Despite Beating Q1 Estimates
Stock Track | AbCellera Biologics Soars 7.62% After-Hours on Earnings Beat and Positive Clinical Data
Stock Track  ·  05-12
Stock Track | AbCellera Biologics Soars 7.62% After-Hours on Earnings Beat and Positive Clinical Data
Earnings Flash (ABCL) AbCellera Biologics Posts Q1 Per Share Loss of $0.14, vs. FactSet Est Loss $0.17
MT Newswires Live  ·  05-12
Earnings Flash (ABCL) AbCellera Biologics Posts Q1 Per Share Loss of $0.14, vs. FactSet Est Loss $0.17
AbCellera Biologics Q1 Loss Narrows, Revenue Rises
MT Newswires Live  ·  05-12
AbCellera Biologics Q1 Loss Narrows, Revenue Rises
Abcellera Biologics Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-12
Abcellera Biologics Inc reports results for the quarter ended March 31 - Earnings Summary
AbCellera Q1 revenue more than doubles, beats estimates
Reuters  ·  05-12
AbCellera Q1 revenue more than doubles, beats estimates
AbCellera Q1 FY26 net loss narrows to $43.2 million; revenue rises to $8.3 million
Reuters  ·  05-12
AbCellera Q1 FY26 net loss narrows to $43.2 million; revenue rises to $8.3 million
AbCellera Biologics Q1 EPS $(0.14) Beats $(0.20) Estimate, Sales $8.315M Beat $5.856M Estimate
Benzinga  ·  05-12
AbCellera Biologics Q1 EPS $(0.14) Beats $(0.20) Estimate, Sales $8.315M Beat $5.856M Estimate
BRIEF-AbCellera Q1 Revenue USD 8.3 Million Vs. IBES Estimate USD 5.86 Million
Reuters  ·  05-12
BRIEF-AbCellera Q1 Revenue USD 8.3 Million Vs. IBES Estimate USD 5.86 Million
Abcellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for Abcl635
THOMSON REUTERS  ·  05-12
Abcellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for Abcl635
Press Release: AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
Dow Jones  ·  05-12
Press Release: AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  05-11
Calendar of U.S. Earnings Expected in the Week Ahead

Introduction

Company Name.
AbCellera Biologics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Issue price:
--